Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck/ Genmab to develop CNS therapy

Lundbeck has entered into a collaboration with Genmab to create and develop human antibody therapeutics for central nervous system disorders

Danish pharmaceutical company Lundbeck has entered into a collaboration deal with biotech company Genmab to create and develop human antibody therapeutics for central nervous system (CNS) disorders.

Under the terms of the agreement, Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will gain access to Genmab's fully automated, state of the art pre-clinical antibody screening and characterisation capabilities including its proprietary stabilised IgG4 and UniBody therapeutic antibody platforms. 

The agreement also allows for Lundbeck to take selected antibodies into clinical development at its own cost and subject to the payment of milestones and royalties to Genmab. Genmab will have the option to take selected antibodies into clinical development for some pre-defined non-CNS indications subject to similar terms relating to costs, milestones and royalties.

The deal could be worth €38m in total. Genmab will receive an upfront payment of €7.5m, with further payments on achievement of agreed milestones. The biotech firm will also be entitled to single digit royalties. The development of the antibodies will be fully funded by Lundbeck. 

"Genmab's broad antibody development expertise and Lundbeck's knowledge in CNS disorders is an ideal combination for developing new treatments in this important therapeutic area," said Peter Høngaard Andersen, executive vice president, head of research at Lundbeck. "The new partnership follows Lundbeck's new R&D strategy to ensure we have the most efficient platform for the future discovery and development of drugs that will be able to help and treat biologically defined groups of patients with brain diseases. It is this type of drug we expect will be in demand in the future."

Jan van de Winkel, chief executive officer of Genmab said: "We are pleased to enter into this collaboration with Lundbeck, world experts in the development of CNS therapeutics. It gives Genmab the opportunity to leverage our antibody technology and expertise and to expand our pipeline into a new and exciting therapeutic area without assuming a financial obligation."

Neither Lundbeck nor Genmab expect this deal to have an impact on the companies' financial guidance for 2010.

13th October 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics